A new analysis of national mortality data in England confirms zero cervical cancer deaths among women aged 20 to 24 between 2020 and 2024, a milestone researchers attribute to the national HPV vaccination programme. According to a study published in The Lancet, the vaccine has prevented approximately 200 cervical cancer deaths to date, with experts projecting a significant rise in lives saved as vaccinated cohorts reach middle age.
How has the HPV vaccine impacted mortality rates?
The impact of the vaccine is most pronounced in the youngest age groups. Researchers led by Peter Sasieni at Queen Mary University of London compared recorded cervical cancer deaths against statistical models of expected mortality without intervention. In the 20–24 age bracket, where roughly nine in ten individuals received the vaccine at age 12 or 13, the observed death count was zero, compared to an estimated 23 deaths had the programme not existed.
While the reduction in the 25–29 age group is also substantial, the effect in the 30–34 group is more difficult to isolate. According to the study, this is because many women in their early thirties were offered the vaccine only in their late teens, potentially after they had already been exposed to the human papillomavirus (HPV). The vaccine is most effective when administered before any viral exposure.
Nearly all cervical cancers are caused by HPV, a common sexually transmitted infection. Without vaccination, an estimated 80% of people will contract the virus at some point in their lifetime.
Why are experts concerned about vaccination coverage?
Despite the success in preventing deaths, experts warn that the progress is fragile. The World Health Organization (WHO) identifies a 90% vaccination coverage rate as the threshold required to eliminate cervical cancer as a public health problem. In England, however, uptake has fallen; data for the 2024–2025 period shows that only 76% of girls were vaccinated by age 15.
Michelle Mitchell, chief executive of Cancer Research UK, described the findings as an “incredible milestone” but emphasized that the current decline in uptake requires an urgent government response. She noted that health systems must implement targeted strategies to reach communities where vaccination rates remain the lowest to ensure the gains of the last two decades are not reversed.
What are the future trends for cervical cancer prevention?
The long-term efficacy of the vaccination programme will become clearer over the next two decades. Cervical cancer deaths typically begin to rise when women reach their late thirties and forties. As the first generation of vaccinated women moves into these age brackets, researchers expect the number of prevented deaths to grow rapidly.
Previous concerns that the vaccine might only prevent early-stage cancers—which could have been caught by routine screening—have been addressed by the latest data. The study confirms that the vaccine is successfully preventing the advanced-stage cancers that historically caused the majority of fatalities. This reinforces the role of the HPV vaccine as the cornerstone of global elimination efforts.
Frequently Asked Questions
Does the HPV vaccine guarantee total protection?
No medical intervention is 100% effective, but the vaccine protects against the two strains, HPV16 and HPV18, which are responsible for the vast majority of cervical cancers. Routine screening remains a vital component of cervical health.
Why is the vaccination age important?
According to researchers, the vaccine works best when administered before an individual is exposed to the virus. This is why national programmes typically target adolescents aged 12 to 13.
Can the vaccine prevent deaths in older women?
While the greatest impact is seen in those vaccinated before exposure, the programme continues to save lives. As more vaccinated cohorts reach the age where cancer risks typically increase, the cumulative number of lives saved is projected to rise significantly.
Are you interested in how public health initiatives are shaping the future of cancer care? Subscribe to our newsletter for the latest updates on medical research and health policy.
Keep reading
